Dirk Schadendorf

University Hospital Essen

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Cancer Biology Cancer Biology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (8)

Ralf Gutzmer

Ruhr-Universität Bochum

GERMANY

View details

Claus Garbe

Professor of Dermatology

Eberhard Karls Universität Tübingen

GERMANY

View details

Titus Josef Brinker

Clinician Scientist / Head of App Development

University Hospital Heidelberg

GERMANY

View details

Helen Gogas

Head, Professor in Medical Oncology,

National and Kapodistrian University of Athens

GREECE

View details

Markus V Heppt

Universitätsklinikum Erlangen

GERMANY

View details

Elisabeth Livingstone

University Hospital Essen

GERMANY

View details

Piotr Rutkowski

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

POLAND

View details

Céleste Lebbé

Université Paris Cité

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dirk Schadendorf

Research Interests

Explore related searches

Contact this professor

Articles (11)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma

Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV Heart Aging Study compared to the general population

Deep learning detection of melanoma metastases in lymph nodes

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus‐19 vaccine‐associated lymphadenopathy

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence

Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanoma

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for<i>BRAF</i>V600–Mutant Unresectable or Metastatic Melanoma

Collaborators (8)

Ralf Gutzmer

Claus Garbe

Titus Josef Brinker

Helen Gogas

Markus V Heppt

Elisabeth Livingstone

Piotr Rutkowski

Céleste Lebbé

Make your next move.